Patients were randomly assigned to receive an extended-release aqueous-gel formulation of lanreotide ( Autogel [ known in the United States as Depot ] , Ipsen ) at a dose of 120 mg ( 101 patients ) or placebo ( 103 patients ) once every 28 days for 96 weeks .